Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

HAVN Life Sciences Stock News

HAVLFOTCEM

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

HAVN Life Sciences (HAVLF) Forecast

News

Earnings HAVN Life Sciences (HAVLF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest HAVN Life Sciences Stock News | OTC:HAVLF | Benzinga

Get the latest news on HAVN Life Sciences stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on HAVN Life Sciences performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, July 31, 2024

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Javier Hasse

Thursday, October 06, 2022

This Legal Psychoactive Mushroom Reduces Stress And Pain And Encourages Longevity, Expert Says
Natan Ponieman

Friday, August 19, 2022

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance
Lara Goldstein

Monday, August 01, 2022

Learn About HAVN Life's New Shares Consolidation, What Changes And What Remains
Lara Goldstein

Thursday, July 28, 2022

Canada-Based Project Solace Aims To Provide Access And Data On Medical Psilocybin
Lara Goldstein

Tuesday, June 28, 2022

HAVN Life Sciences & Optimi Health Corp Announce Supply Agreements, Here Are The Details
Lara Goldstein

Monday, February 14, 2022

Psyched: Cathie Wood Invests In Psychedelics Co ATAI, Bill Approved in Utah, AI Startup To 'Design States Of Mind'
Natan Ponieman

Friday, February 11, 2022

HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
Nicolas Jose Rodriguez

Monday, December 20, 2021

Havn Life Buys Subscription-Based Functional Mushroom Co. With Significant US Consumer Base
Jelena Martinovic

Tuesday, November 23, 2021

HAVN Life Successfully Exports Naturally Derived Psilocybin From Its Jamaica Facility Into Canada
David Carpenter

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman

Thursday, October 07, 2021

Former Tilray CEO Joins Psychedelics Company
Natan Ponieman

Monday, September 27, 2021

Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
Natan Ponieman

Monday, September 13, 2021

Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Natan Ponieman

Monday, August 30, 2021

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Natan Ponieman

Monday, August 02, 2021

Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Natan Ponieman

Monday, May 17, 2021

Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Natan Ponieman

Monday, May 10, 2021

Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
Natan Ponieman

Saturday, February 06, 2021

Psyched: Boston Suburbs Decriminalize Psilocybin, Delic Begins Psychedelic Treatments, Australia Denies Legalization
Natan Ponieman

Sunday, January 31, 2021

Psyched: First Psychedelics ETF Debuts; Hawaii, Florida and Connecticut Eye Psilocybin Legalization; Psyence Goes Public
Natan Ponieman

Wednesday, January 27, 2021

First Psychedelics ETF Debuts On NEO Exchange
Natan Ponieman

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved